Invitrogen™ Lendalizumab Recombinant Monoclonal Antibody

Description

For reconstitution, add sterile, distilled water to achieve a final antibody concentration of 1 mg/mL. Gently shake to solubilize the protein completely. Do not vortex. Reconstituted products should be stored at -80 °.

Lendalizumab, also known as an anti-C5 antibody, is a human monoclonal antibody targeting complement component 5 (C5). Complement component 5 (C5) is a vital protein in the complement system, part of the innate immune response. It is coded by the C5 gene located on chromosome 9, and consists of alpha and beta polypeptide chains. Activation of C5 occurs through the cleavage by C5 convertases in the classical, lectin, or alternative pathways, resulting in two fragments, C5a and C5b. C5a acts as an anaphylatoxin, promoting inflammation by stimulating chemotaxis and activating various immune cells. C5b initiates assembly of the membrane attack complex (MAC), leading to cell lysis. Dysregulation of C5 has been associated with autoimmune diseases such as myasthenia gravis and collagen-induced arthritis. Recent studies have explored the use of siRNA targeting C5 to mitigate disease symptoms by inhibiting C5 activation and subsequent inflammatory responses.